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Randomized controlled trial of intravenous antivenom versus placebo 
for latrodectism: the second redback antivenom evaluation (RAVE- II) 
study. 
Abstract 
Objective: Latrodectism is the most important spider envenomation syndrome worldwide. 
There remains considerable controversy over antivenom treatment. We aimed to 
investigate whether antivenom resulted in resolution of pain and systemic effects in 
patients with latrodectism given standardized analgesia.  
Methods: In a multicentre randomized placebo-controlled trial of redback spider 
antivenom for latrodectism, 224 patients (>7yr) with a redback spider-bite and severe 
pain with or without systemic effects were randomized to receive normal saline (placebo) 
or antivenom, after receiving standardized analgesia. The primary outcome was a 
clinically significant reduction in pain 2 hours after trial medication compared to 
baseline. A second primary outcome for the subgroup with systemic features of 
envenomation was resolution of systemic features at 2 hours. Secondary outcomes were 
improved pain at 4 and 24 hours, resolution of systemic features at 4 hours, 
administration of opioid analgesics or unblinded antivenom after 2 hours and adverse 
reactions.  
Results: Two hours after treatment, 26/112 patients (23%) from the placebo arm had a 
clinically significant improvement in pain versus 38/112 (34%) from the antivenom arm 
(difference in favor of antivenom 10.7%;95%CI:−1.1% to +22.6%;p=0.10). Systemic 
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effects resolved after two hours in 9/41 patients (22%) in the placebo arm and 9/35 (26%) 
in the antivenom arm (difference 3.8%;95%CI:−15% to +23%;p=0.79). There was no 
significant difference in any secondary outcome between antivenom and placebo. Acute 
systemic hypersensitivity reactions occurred in 4/112 (3.6%) patients given antivenom.  
Conclusions: The addition of antivenom to standardized analgesia in patients with 
latrodectism, did not significantly improve pain or systemic effects.  
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Introduction 
Spider bite is a common problem worldwide.1 Latrodectism is the most common severe 
spider envenoming syndrome and is caused by widow spider (Latrodectus spp.) bites, 
particularly in warmer parts of America, Europe, and Australia.2-4 In Australia there are 
3000 to 5000 cases every year.3 Widow spiders are medium sized black spiders that vary 
in appearance and include 30 species on most continents.5 Envenoming is characterized 
by local, regional or generalized pain associated with systemic symptoms and autonomic 
effects. The severity and features of latrodectism appears to vary for different widow 
spiders from different regions,2-4,6-9 but pain is the most prominent feature in all cases. 
Despite the medical importance of latrodectism, treatment continues to be problematic 
with wide variations in clinical practice worldwide.1 Antivenom is only available in some 
countries,10 and there is controversy regarding its effectiveness and safety.1 In the United 
States there has been limited use of antivenom due to the perceived risks of adverse 
reactions following a death attributed to antivenom.4 In Australia, a highly purified 
equine antivenom raised against the local species Latrodectus hasselti (redback spider) 
has been widely used for 60 years, mainly by the intramuscular route. Its introduction 
was prior to the era of randomized controlled clinical trials. Numerous other treatments 
with little evidence for effectiveness have been used, including benzodiazepines, calcium, 
magnesium and combinations of non-opioid and opioid oral analgesia.1 
Three randomized controlled trials of antivenom for latrodectism have been 
published.2,11,12 Two previous trials in Australia both reported no difference between 
intravenous and intramuscular antivenom.2,11 These were unexpected outcomes because it 
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was assumed that intravenous antivenom would be more effective. In addition, a 
pharmacokinetic analysis of a subgroup of patients from one trial found that antivenom 
was only detectable in serum after intravenous administration.13 A small phase II study of 
black widow spider antivenom versus placebo found no significant benefit of antivenom 
over placebo.12 Taken together, these results suggested that antivenom might be no more 
effective than placebo and provided sufficient doubt to warrant a placebo-controlled trial. 
The aim of this study was therefore to determine whether the administration of redback 
spider antivenom is superior to placebo for treating the pain and systemic effects of 
latrodectism in patients already receiving standardized analgesic treatment. 
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Methods 
This was a placebo-randomized controlled trial of red-back spider antivenom in patients 
with moderate to severe latrodectism (redback spider envenoming) with a primary 
outcome of a clinically significant reduction in pain two hours after the trial medication 
(compared to baseline).  A second primary outcome for the subgroup with systemic 
features of envenoming was the resolution of these features also at two hours. Two 
primary endpoints were chosen because both types of response are clinically important 
but not necessarily linked. All participants received analgesia according to a standardized 
protocol, commenced prior to the administration of trial drug or placebo. The study was 
approved by seven Human Research Ethics Committees to cover all hospital sites. The 
trial was registered with the Australian New Zealand Clinical Trials Registry, 
http://www.anzctr.org.au/, ACTRN12609000063213. 
Study Patients 
Patients were recruited from 20 emergency departments around Australia between 
January 2009 and June 2013 if they had a redback spider bite and the treating clinician 
would normally administer antivenom or analgesia for the pain, or systemic envenoming. 
A redback spider bite was defined as either a bite by a spider which was clearly identified 
as a redback spider (by the patient or clinician) or a clinical syndrome consistent with 
typical redback spider envenoming, that is the sensation of a bite followed by two or 
more of (increasing pain over the first hour, radiating, regional or generalized pain, local 
or regional diaphoresis).  
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Local envenoming was defined as severe local pain, for which the patient was requesting 
analgesia, or that was preventing sleep. Systemic envenoming was defined as the 
presence of ≥3 of the following: nausea, vomiting, headache, lethargy, malaise and 
abdominal pain.  
Exclusion criteria were age less than 8 years (due to the unreliability of the Verbal 
Numerical Rating Scale (VNRS) for assessment of pain in this group), prior 
administration of antivenom and presentation to hospital more than 36 hours after the 
bite.  
Treatment Protocol 
Patients were identified by nursing or medical staff on or soon after admission. It was not 
possible to keep a record of patients with redback spider bites not recruited to the study 
because the investigators were only contacted for patients that met the inclusion criteria. 
The study was explained and written informed consent was obtained from the patient or 
the parent/guardian of the patient. The treating doctor then contacted a national free-call 
telephone number to enroll the patient and receive a randomization code. The patient was 
put in an acute observation area with cardiac monitoring, pulse oximetry and automated 
blood pressure measurements, and an intravenous cannula was inserted.  
All patients received a standard analgesia protocol prior to receiving the study 
intervention with oral paracetamol 1g (20mg/kg up to a maximum of 1g in children), 
ibuprofen 800mg (10mg/kg up to a maximum of 800mg in children) and oxycodone 5mg  
(0.1mg/kg up to a maximum of 5mg in children). 
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The Calvary Mater Newcastle pharmacy in conjunction with Richard Stenlake 
Compounding Chemist produced pre-packed kits for the trial. Each treatment kit 
contained two vials of either redback spider antivenom or normal saline. Normal redback 
spider antivenom vials (equine F[ab’]2 antivenom, 500U/vial, raised against L. hasselti) 
as well as identical empty vials were purchased from CSL Ltd. The compounding 
chemist filled the identical (empty) vials with normal saline, which was visually 
indistinguishable from antivenom. Labels were removed from vials and the central 
pharmacy re-labeled the vials with study numbers. Each kit was then randomized to 
contain either two vials of antivenom (active) or two vials of normal saline (placebo).  
Block randomization was used (with variable block-sizes of 2 and 4) with stratification 
between local and systemic envenoming. Block sizes of 2 and 4 meant that each pack of 
four randomized treatments provided to the hospital might feasibly contain any 
combination of placebo and antivenom (including four antivenom or four placebo), 
making it impossible to predict the last kit in each pack. During the study each site was 
kept stocked with 2 packs each containing 4 treatment kits, one pack of 4 for local 
envenoming and the other for systemic envenoming.  
Using a pre-randomized list of blocks, the chief investigators and on-call research 
assistants allocated study codes to patients in sequential order based on the hospital site 
and whether the patient had systemic effects or not. The study code was then used to 
identify the correct trial pack stored at the site. The content of each treatment pack (active 
or placebo) was only known by the centralized pharmacy so that treating clinicians, 
patients and investigators were blind to the study intervention. 
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The trial drug was administered (2 vials of placebo or two vials of redback spider 
antivenom) mixed in 200 mL normal saline over 20 minutes. The patient had continuous 
monitoring (electrocardiogram, pulse oximetry and non-invasive blood pressure) during 
the infusion of the study drug and for 30 minutes after completion. Study observations 
were performed at 2 hours and 4 hours after infusion commencement and patients 
remained in hospital until at least 4 hours after the study drug. Further study observations 
were done immediately prior to discharge if kept in hospital for longer than 4 hours.  
After measurement of the primary endpoint 2 hours from study commencement, 
parenteral opioid analgesia (e.g. morphine) and (unblinded) doses of redback spider 
antivenom were permitted and their use determined by the treating doctor. All patients 
were given regular ibuprofen (400mg three times daily) for 24 to 48 hours and oxycodone 
as required following the 4-hour study period.   
Data Collection 
Data collected on case report forms included patient demographics, details of the bite 
(spider identification, circumstances of the bite), baseline clinical effects, serial clinical 
effects during the study, additional treatment (analgesia and unblinded redback spider 
antivenom) and adverse reactions. Pain was assessed using a verbal numeric rating scale 
(VNRS) which required the patient to verbally provide a score between 0 and 10 
inclusive where 0 represented “no pain” and 10 “worst pain possible”. Immediate-type 
hypersensitivity reactions were recorded according to a previously published grading 
scale as skin only systemic hypersensitivity reactions, anaphylaxis or severe anaphylaxis 
(hypotension or hypoxia).14 
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Patients were followed up by telephone by a research assistant at 24 hours from the time 
of administration of the study treatment, 7 to 10 days and 6 weeks to assess for 
effectiveness and adverse events including symptoms of serum sickness. The research 
assistant used a proforma to ask the patient pre-defined questions, including the VNRS, if 
any further analgesia was used, whether the patient was re-admitted to the emergency 
department/hospital or visited their local doctor. In addition, they would ask about each 
of the symptoms of serum sickness at the 7 to 10 day and 6 week follow up. 
Data Analysis 
The first primary outcome was a clinically significant reduction in the severity of pain 2 
hours after the commencement of the study treatment using the VNRS. This was 
dependent on the baseline starting point – a reduction of 2 or greater was required for 
baseline score of 0 to 3, 3 or greater for a baseline score of 4 or 5, 4 or greater for a 
baseline score of 6 or 7, and 5 or greater for a baseline score of 8 to 10. This approach 
was similar to that previously used in the RAVE I study (see Appendix).2  The required 
reduction for each baseline  score was modified slightly after trial registration but prior to 
unblinding of the data, because of an inconsistency in the registered method that would 
have given inconsistent results in patients with similar scores (see Appendix). The second 
primary outcome was a resolution of systemic features of envenoming within 2 hours, in 
the subgroup of patients with systemic envenoming. Resolution of systemic envenoming 
was defined as not having more than one remaining systemic symptom/feature. Both 
primary outcomes were analyzed by intention to treat. 
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Secondary outcomes were pre-defined as – clinically significant reduction in pain and 
resolution of systemic features (if present) at 4 hours (same definition of resolution as at 2 
hours), administration of opioid analgesics (oral or parenteral) or further doses of 
antivenom after 2 hours, a clinically significant reduction in pain at 24 hours, use of 
opioid analgesia after discharge, re-presentations for medical care, acute systemic 
hypersensitivity reactions and serum sickness defined as 3 or more characteristic 
symptoms (fever, malaise, rash, itchiness, myalgia, arthralgia). Predefined subgroup 
analyses were planned for patients with systemic envenoming. 
A sample size of 240 (including 94 patients with systemic effects) was calculated to give 
80% power to detect a 20% difference in the primary outcome of clinically significant 
pain reduction (regarded to be a clinically important difference by clinicians15) and/or a 
30% difference in the primary outcome of resolution of systemic effects. The study was 
stopped early (16 patients short of the sample size) because there was no further funding 
to re-supply all 20 hospitals with antivenom and placebo trial packs which expired 
annually and had to be replaced prior to the next bite season. 
Once the study was finished and all data entered into the study database, the chief clinical 
investigator (GI) remained blinded to the allocation and audited all primary and 
secondary outcomes against original datasheets and clinical notes. If an inconsistency 
was identified, a second investigator (SGAB or CP) adjudicated. During this stage only 
the study numbers, not group allocation, were known to these investigators. One 
investigator, not involved with the day-to-day conduct of the study (NB) was then 
supplied with the blinded data and separately with the group allocation as either “A” or 
“B” by the central pharmacy. He undertook the study analysis independently and 
11 
 
presented this to the writing group. The final analysis was then approved before the 
central pharmacy revealed whether “A” or “B” was antivenom. 
Statistical methods.  
Continuous variables were presented as medians with interquartile ranges (IQR) and 
proportions were given with 95% confidence intervals (CIs). Dichotomous primary 
outcomes were analyzed using a two-tailed Fisher’s exact test (p<0.05 to be significant). 
Continuous secondary outcomes were analyzed by either a t-test (parametric) or Mann-
Whitney test (non-parametric). A post-hoc analysis was performed with the primary pain 
outcome as a continuous variable according to percent pain reduction. This also explored 
whether there was any effect of time from the bite to antivenom on response in the 
antivenom arm using linear regression. All analyses and graphs were done with GraphPad 
Prism version 5.03 for Windows (GraphPad Software, San Diego California USA, 
www.graphpad.com).  
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Results 
Of 227 patients recruited to the study, 224 were randomized and received their allocated 
treatment. Two patients were inadvertently given unblinded antivenom rather than the 
trial drug and one did not have the trial drug code recorded. One hundred and twelve 
patients were randomized to receive normal saline (placebo arm) and 112 to receive 
redback spider antivenom (Figure 1). The two study arms had similar baseline 
characteristics although the placebo group tended to present earlier, had more patients 
with an initial pain score of 8 to 10, and fewer patients were given prior analgesia (Table 
1). There were 76 patients (34%) with systemic effects and 176 patients (79%) developed 
diaphoresis (local [111, 50%], regional [31, 14%] and generalized [34, 15%]). 
Primary Outcomes 
Two hours after treatment, 26 of 112 patients (23%) from the placebo arm had clinically 
improved pain versus 38 of 112 patients (34%) from the antivenom arm (difference in 
favor of antivenom 10.7%; 95% CI: -1.1% to +22.6%; p=0.10)(Table 2). The change in 
pain score for individual patients comparing placebo to antivenom in shown in Figure 2 
and the percentage reduction in pain scores in Figure 3 and Table 3. Additional analyses 
of the primary outcome using absolute (non-weighted) and relative measures of changes 
in pain had no significant difference between placebo and antivenom (See Appendix and 
Table 3). Systemic effects resolved after two hours in 9 of 41 patients (22%) patients in 
the placebo arm compared to 9 of 35 patients (26%) in the antivenom arm (difference 
3.8%; 95% CI: -15% to +23%; p=0.79).  
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Secondary Outcomes 
There was no significant difference between placebo and antivenom for the improvement 
in pain at 4 hours and 24 hours (Table 2). Figure 4 shows the change in pain over the 
study period including pain on follow up at 7 to 10 days and at 6 weeks. There was also 
no difference in the resolution of systemic effects between placebo and antivenom.  
In total 135 patients required rescue opioid analgesia, 77 receiving an oral opioid 
(oxycodone, codeine or tramadol), 29 receiving parenteral opioids (morphine, fentanyl) 
and 29 receiving both. Fifty nine patients were given unblinded antivenom 2 or more 
hours after the study treatment. More patients in the placebo group were given rescue 
opioid analgesia and unblinded antivenom, although these differences were not 
statistically significant (Table 2). 
Post-hoc analysis of effectiveness data 
Combining the primary outcomes to measure those with either a significant reduction in 
pain OR systemic features did not alter conclusions about the lack of effectiveness 
(30/112 [27%] in the placebo arm versus 41/112 (37%) in the antivenom arm; (difference 
9.8%, 95%CI: −2.4% to +22%; p=0.15). Using the registered primary pain outcome (with 
the statistical inconsistency) also did not change conclusions (21/112 [19%] in the 
placebo arm versus 31/112 (28%) in the antivenom arm; (difference 9.8%, 95%CI: −2.4% 
to +22%; p=15). The median percent pain reduction was 25% in placebo arm compared 
to 33% in antivenom arm, (Figure 3, Mann Whitney P=0.0517). However, there was no 
relationship between percent pain reduction and time from bite to antivenom in the 
antivenom arm (Supplementary Figure 1).  Response rates were equally poor when 
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comparing confirmed (spider identified) and non-confirmed bites (see Table 3 and 
Appendix).  
Adverse Reactions 
Acute skin only (mild) hypersensitivity reactions occurred in 4 of the 112 patients (3.6%) 
given antivenom and none in the placebo group. Twenty one patients (9%) developed 
symptoms consistent with serum sickness and five of these presented to the emergency 
department or local doctor. There was no difference in reports of ‘serum sickness’ 
between those randomized to antivenom and placebo, although slightly fewer cases 
occurred once the use of unblinded antivenom was accounted for (Table 2). Eighteen 
(8%) patients represented to either the emergency department (11) or their local doctor 
(7), 12 of these for ongoing pain for symptoms of the bite. This did not differ between 
placebo and antivenom arms. 
Limitations 
A potential limitation of the study was the sample size being too small to completely 
exclude a small benefit. It is possible that a larger study might find a beneficial treatment 
effect of antivenom, but the effect is very likely to be small. This study was powered to 
detect a difference of 20% (NNT ≤ 5). It is important to consider that redback spider 
antivenom is used as an analgesic and not to save lives. The NNT in trials of effective 
analgesics range from 2 to 4 in meta-analyses.16 Much higher NNT are not clinically 
significant for studies of analgesia. In other words, if the study was larger and showed a 
statistically significant and similar absolute difference in the order of 10%, (NNT = 10), 
ten patients would need to be given antivenom for one patient to get significant pain 
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relief. This is a very poor result for pain relief and also must be balanced against the risk 
of a hypersensitivity reaction of around 4% in this and previous studies (i.e. numbers 
needed to harm = 25).2,17 It is important to note that neither our standard analgesia nor 
analgesia and antivenom resulted in pain resolution in three quarters of the patients so 
further trials are needed to investigate alternate and more effective treatments, whether or 
not antivenom has a marginal effect. 
Another limitation of the study was that some cases were included based on a clinical 
diagnosis of latrodectism rather than a definite bite. However, our clinical definition has 
been validated by a prospective study of identified spider bites18 and re-analysis of the 
primary outcomes including only cases where the spider was identified resulted in the 
same outcomes.  
Finally, the outcomes we used have not been fully validated which may have resulted in 
either under-estimation or over-estimation of the measured effect for both pain and 
systemic effects. However, this would have affected both arms of the study. A similar 
primary pain outcome has been used in two previous studies, one positive and one 
negative.2,19  
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Discussion 
This trial demonstrates that the addition of redback spider antivenom to a standardized 
analgesic treatment protocol in patients with latrodectism (redback spider envenoming), 
did not significantly improve pain or systemic effects. Patients responded poorly to 
analgesia alone or analgesia plus antivenom, with only a quarter of patients on average 
having an improvement at 2 hours. There were also no differences in secondary outcomes 
between the placebo group and the antivenom group. 
The use of antivenom in latrodectism has always been contentious because it is not a life-
threatening envenoming syndrome. Therefore, clear benefits of antivenom over standard 
care are required to balance against the known but small risk of anaphylaxis to the 
antivenom. In our study, more patients had an improvement in pain in the antivenom 
group at 2 hours, but this did not reach statistical significance and there was no evident 
treatment effect on systemic envenoming. Furthermore, there was also a slight imbalance 
between the placebo and antivenom arms of the study with the antivenom group 
presenting somewhat later and with less patients having high initial pain scores (Table 1). 
This imbalance may favor the pain response in the antivenom group, because later-
presenting patients are further down the pathway of spontaneous recovery by the time of 
randomization. Later presentation of the antivenom group could alternatively favor the 
placebo group if antivenom has a time-dependent effect, but there was no relationship 
between the time to antivenom and the pain response in the antivenom group 
(Supplementary Figure 1). This indicates that redback spider antivenom is not more likely 
to be effective if given earlier, which is not consistent with the expected effect of 
antivenoms. 
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A number of in vitro studies have demonstrated that redback spider antivenom is able to 
neutralize the effects of the venom.20-22 In addition, Graudins et al showed that redback 
spider antivenom was able to prevent in vitro neurotoxicity in a chick isolated biventer 
cervicis nerve-muscle preparation and lethality in mice, from a range of widow spider 
venoms.21 Daly et al also showed that redback spider antivenom prevented the lethal 
effects of L. Hesperus and L. mactans.22 It is therefore highly unlikely that poor clinical 
effectiveness in our study is due to the antivenom having poor binding or neutralization 
properties. The likely reason for treatment failure is that in vitro antivenom efficacy does 
not always translate into clinical effectiveness. The antivenom has not been shown to 
distribute to the peripheral site of the envenoming syndrome. Nor has it been shown to 
bind to the toxin at its site of action and reverse pathophysiological changes. To be 
clinically effective an antivenom must be capable of doing both, and there are several 
previous examples of antivenoms that cannot reverse pathophysiology and are therefore 
not capable of significantly improving clinical outcomes.23  
A better understanding of the pathophysiology of latrodectism is required so that 
effective treatments can be developed. This study and previous work suggests that 
standard analgesic treatment is also unable to provide relief for patients. Other treatments 
such as calcium, magnesium and muscle relaxants have never been tested in a controlled 
way in patients. Potentially treatments used for neuropathic pain, such as gabapentin, 
could also be trialed.  
The study cannot be immediately generalized to other widow spider antivenoms.10 All 
widow spiders are closely related and a recent study has shown that the redback spider (L. 
hasselti) and both American black widow spiders (L. mactans, L. hesperus), contain 
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similar neurotoxins to α-latrotoxin, originally identified in the European widow spider (L. 
tredecimguttatus).24 In addition, animal studies have demonstrated cross-neutralisation of 
black widow spider venoms by redback spider antivenom.21,22 The study therefore 
provides some support for the idea that widow spider antivenoms may not be effective. 
The only other placebo randomized controlled trial of widow spider antivenom was also a 
negative trial.12 However, further and larger studies are required for different widow 
spiders and antivenoms.   
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Figure Legends 
Figure 1: Flow chart of all persons recruited to the study, their allocation to placebo or 
antivenom and the two primary outcomes.  
Figure 2: A waterfall plot showing all individual changes in pain score between baseline 
and 2 hours in each group ordered according to baseline score and then response.  
Baseline score is shown as small black bar and the vertical bars indicate the movement 
with worsening pain shown as a checkered pattern and improvements shown in grey, with 
the darker grey indicating they met criteria for a significant change in pain scores (pre-
specified primary outcome). 
Figure 3: Scatter plot of the percentage change in the pain score from baseline to the 2 
hour pain score comparing placebo versus antivenom, including lines marking the median 
and interquartile range.   
Figure 4: Box plots of the pain score for all time points including on follow up at 7 to 10 
days and at 6 weeks. Patients given placebo are in white and those given antivenom in 
grey. The boxes are the 25th to 75th percentile and the whiskers are 5 to 95 percentiles. 
Supplementary Figure 1: A linear logarithmic plot of the percent reduction in pain for 
the antivenom arm versus the time from bite to antivenom (top panel) and the placebo 
arm versus the time from bite to antivenom (bottom panel). The solid line and shaded 
area represent the line of best fit by linear regression and the 95% confidence band.  
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Table 1: Baseline characteristics  
Baseline parameters 
Placebo 
n=112 
Antivenom 
n=112 
Age (Median;IQR) 40.0 (26.0-54.0) 39.0 (31.8-54.0) 
Male  55 49% 59 53% 
Baseline Pain score1         
2-3 7 6% 10 9% 
4-5 20 18% 22 20% 
6-7 36 32% 42 38% 
8-10 49 44% 37 33% 
Spider Identified 87 78% 84 75% 
Bite site (n=109, 111)         
Distal limb 58 53% 70 63% 
Proximal Limb 26 24% 28 25% 
Trunk/head/neck 25 23% 13 12% 
Time to Study Treatment 
(Median;IQR) 2.0 (1.1-9.5) 2.7 (1.0-14.8) 
Time from Analgesia to 
Treatment (Median;IQR) 0.5 (0.23-1.06) 0.5 (0.17-0.99) 
Prior Analgesia         
Yes 47 42% 58 52% 
No 52 46% 49 44% 
Not recorded 13 12% 5 4% 
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Diaphoresis     
Nil 24 21% 24 21% 
Local 56 50% 55 49% 
Regional 14 13% 17 15% 
Generalized 18 16% 16 14% 
Systemic Effects 41 37% 35 31% 
IQR – interquartile range; 1 one patient in the antivenom group had a baseline pain score of zero 
because there was a delay with the trial drug. 
 
27 
 
Table 2: The primary and secondary outcomes for the study.  
Outcomes Number2 Placebo % Antivenom % Difference (95%CI) P value 
Primary Outcome (Pain 2h)   26 23% 38 34% 10.7% -1.1% to +22.6% 0.1034 
Primary Outcome (Systemic 2h) (n=41, 35) 9 22% 9 26% 3.8% -15% to +23% 0.7894 
4hr Pain Reduction (n=105, 106) 46 44% 56 53% 9.0% -4.5% to +23% 0.2159 
24hr Pain Reduction (n=105, 107) 57 54% 67 63% 8.3% -5% to +22% 0.2649 
4 hr Systemic Resolved (n=41, 34) 23 56% 21 62% 5.7% -17% to +28% 0.6455 
Rescue Opiate 
 
73 65% 62 55% -9.8% -3% to +23% 0.172 
Unblinded Antivenom 
 
36 32% 23 21% -11.6% -23% to 0% 0.0682 
PRN Analgesia   25 22% 29 26% 3.6% -8% to +15% 0.6396 
Serum Sickness   9 8% 12 11% 2.7% -5% to +10% 0.6476 
Serum Sickness(No unblind AV)1 (n=76, 89) 5 7% 9 10% 3.5% -‡ 0.5770 
Acute Reactions  0 0% 4 3.6% 3.6% - 0.1216 
Repeat Presentations   11 10% 7 6% -3.6% -11% to +3% 0.4619 
1 Serum sickness occurring in patients who were not also given additional labeled antivenom; AV – antivenom; 2 112 unless otherwise stated 
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Table 3: Additional primary outcome analyses and sensitivity analyses of the primary outcome. 
Primary Outcome (pain at 2h) Placebo % Antivenom % Diff. (95%CI) P value 
Final definition (as per study) 
Original registered definition 
Median absolute change VNRS (IQR) 
Median relative change (%) VNRS (IQR) 
26 
21 
2 
25% 
23% 
19% 
0 to 3 
0 to 50% 
38 
31 
2 
33% 
34% 
28% 
1 to 4 
12 to 66% 
10.7% 
8.9% 
0 
8.3% 
-1.1% to +22.6% 
-2.1% to +20% 
0 to 1 
0% to +20% 
0.103 
0.154 
0.064 
0.052 
Bites with definite spider ID 
Final definition (as per study) 
Median absolute change VNRS (IQR) 
Median relative change (%) VNRS (IQR) 
N=87 
22 
2 
25% 
 
25% 
1 to 3 
11 to 57% 
N= 84 
29 
2 
38% 
 
35% 
1 to 4 
13 to 63% 
 
9.2% 
0 
12.5% 
 
-4.5% to +23% 
0 to 1 
0% to 20% 
 
0.240 
0.193 
0.15 
Absolute change VNRS > 2 39 35% 51 46% 10.7% -2.1% to +23.6% 0.133 
Baseline Pain (4 or greater) 
Final definition (as per study) 
N=105 
23 
 
22% 
N=101 
33 
 
33% 
 
10.8% 
 
-1.4% to +23% 
 
0.088 
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Appendix – supplementary methods and results 
The definition of the primary outcome for pain severity involved a reduction in the 
VNRS that was dependent on the baseline starting point. Initially this was defined based 
on a study done by Bird and Dickson on the effect of the baseline visual analogue score 
(VAS) on a clinically important detectable change in the VAS 25 We have previously 
defined primary outcomes based on Bird and Dickson that use the VAS, including both a 
positive and a negative randomized controlled trial.2,19 In this study a VNRS was used to 
measure pain because in the previous RAVE-I study it was recognized that a VNRS was 
more feasible than a VAS in a study in multiple busy emergency departments. Previous 
research had demonstrated that there is good correlation between the two scores.26 To 
allow for the categorical nature of the VNRS when using the baseline approach we had 
developed from Bird and Dickson, the change in pain score needed to be a whole number 
(i.e. 16mm became 2 or greater, 33mm became greater than 3, and 45mm became 5 or 
greater). The registered primary outcome therefore had a clinically significant reduction 
in pain defined as: 2 or greater for baseline scores of 0 to 3, greater than 3 for baseline 
scores of 4 to 6, and 5 or greater for baseline scores of 7 to 10. However, prior to 
unblinding of the study is was recognized that this would produce inconsistent results for 
some pain scores – e.g. a person scoring 3 only needed a change of 2 (3 to 1), whereas a 
person scoring 4 needed a change of 4 (4 to 0). A slight modification was made so that a 
clinically significant reduction in pain was defined as: 2 or greater for baseline scores of 0 
to 3, 3 or greater for baseline scores of 4 or 5, 4 or greater for baseline scores of 6 or 7, 
and 5 or greater for baseline scores of 8 to 10.  
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In addition to the pre-defined definition of a clinically significant reduction in pain the 
change in pain was also analysed as an absolute change in the VNRS and a relative 
change (%) in the VNRS as sensitivity analysis. Further sensitivity analyses were done 
that only included cases where the spider was definitely identified and also for patients 
with baseline VNRS of 4 or greater. The additional outcomes and sensitivity analyses are 
included in table 1 and none were significant. The absolute difference in the median 
absolute change in the VNRS was 0 with 95%CI of 0 to 1 (table 1), which does not cross 
1.3/1.4 (equivalent to a minimally clinically significant difference defined as 13mm or 
1.4cm)25,26 so there is not a detectable minimally clinically significant difference between 
the two groups. 
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